Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?
11:31am, Tuesday, 16'th Dec 2025
Amicus hits a 52-week high after an 87.6% six-month surge, driven by strong Galafold sales and rising uptake of Pombiliti + Opfolda.
Wall Street Analysts See a 60.61% Upside in Amicus Therapeutics (FOLD): Can the Stock Really Move This High?
10:56am, Friday, 12'th Dec 2025
The consensus price target hints at a 60.6% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
The Best Cheap Stocks Under $10 to Buy in December and 2026
02:51pm, Tuesday, 09'th Dec 2025
Today, we explore how investors can find the best-in-class cheap stocks trading for under $10 a share to buy now.
Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock
01:21pm, Friday, 05'th Dec 2025
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Galafold Continue to Drive Amicus' Top Line in 2026?
11:01am, Friday, 05'th Dec 2025
FOLD leans on rising Galafold sales on the back of strong commercial execution as momentum builds into 2026.
Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue?
12:37pm, Thursday, 04'th Dec 2025
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Think Amicus Therapeutics (FOLD) Could Surge 58.46%: Read This Before Placing a Bet
10:56am, Wednesday, 26'th Nov 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 58.5% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable
AXQ Capital LP Makes New $290,000 Investment in Amicus Therapeutics, Inc. $FOLD
03:34am, Tuesday, 25'th Nov 2025
AXQ Capital LP purchased a new position in Amicus Therapeutics, Inc. (NASDAQ: FOLD) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commi
Amicus Therapeutics: Moving Towards Consistent Profitability
04:56pm, Tuesday, 11'th Nov 2025
Amicus Therapeutics (FOLD) is progressing toward profitability, driven by strong Q3 results and expanding global approvals for its rare disease therapies. FOLD's revenue grew 19.5% year-over-year, wit
Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript
06:11pm, Monday, 10'th Nov 2025
Amicus Therapeutics, Inc. ( FOLD ) UBS Global Healthcare Conference 2025 November 10, 2025 2:45 PM EST Company Participants Jeffrey Castelli - Chief Development Officer Presentation Unknown Analyst Gr
Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade
10:56am, Monday, 10'th Nov 2025
The consensus price target hints at a 76.3% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns
11:41am, Friday, 07'th Nov 2025
EVER, FOLD, LRCX and CBOE make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.
Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues
11:11am, Wednesday, 05'th Nov 2025
FOLD's third-quarter earnings top estimates as rising Galafold and Pombiliti + Opfolda sales lift revenues by 19% year over year.
Compared to Estimates, Amicus Therapeutics (FOLD) Q3 Earnings: A Look at Key Metrics
10:31am, Wednesday, 05'th Nov 2025
Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare w
Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript
03:56pm, Tuesday, 04'th Nov 2025
Amicus Therapeutics, Inc. ( FOLD ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - CEO, President & Di
